{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lu J"],"funding":["national natural science foundation of china","key scientific and technological innovation projects of wenzhou science and technology bureau","key discipline of zhejiang province in medical technology","scientific research foundation of university of south china"],"pagination":["37"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8943949"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(1)"],"pubmed_abstract":["Background
Lung cancer remains a major cause of cancer-related mortality throughout the world at present. Repositioning of existing drugs for other diseases is a promising strategy for cancer therapies, which may rapidly advance potentially promising agents into clinical trials and cut down the cost of drug development. Ciclopirox (CPX), an iron chelator commonly used to treat fungal infections, which has recently been shown to have antitumor activity against a variety of cancers including both solid tumors and hematological malignancies in vitro and in vivo. However, the effect of CPX on non-small cell lung cancer (NSCLC) and the underlying mechanism is still unclear.Methods
CCK-8, clonal formation test and cell cycle detection were used to observe the effect of inhibitor "],"journal":["Cell communication and signaling : CCS"],"pubmed_title":["Ciclopirox targets cellular bioenergetics and activates ER stress to induce apoptosis in non-small cell lung cancer cells."],"pmcid":["PMC8943949"],"funding_grant_id":["First Class","ZY2020017","Category A","31771534","31570772","91954101","211RJC002"],"pubmed_authors":["Li Y","Chen Q","Gong S","Jin Q","Lu X","Lu J","Wang J","Lu B"],"additional_accession":[]},"is_claimable":false,"name":"Ciclopirox targets cellular bioenergetics and activates ER stress to induce apoptosis in non-small cell lung cancer cells.","description":"Background
Lung cancer remains a major cause of cancer-related mortality throughout the world at present. Repositioning of existing drugs for other diseases is a promising strategy for cancer therapies, which may rapidly advance potentially promising agents into clinical trials and cut down the cost of drug development. Ciclopirox (CPX), an iron chelator commonly used to treat fungal infections, which has recently been shown to have antitumor activity against a variety of cancers including both solid tumors and hematological malignancies in vitro and in vivo. However, the effect of CPX on non-small cell lung cancer (NSCLC) and the underlying mechanism is still unclear.Methods
CCK-8, clonal formation test and cell cycle detection were used to observe the effect of inhibitor ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-22T19:15:32.638Z","creation":"2025-04-06T02:39:19.903Z"},"accession":"S-EPMC8943949","cross_references":{"pubmed":["35331268"],"doi":["10.1186/s12964-022-00847-x"]}}